Fosun Pharma: Approved to Publicly Issue Technology Innovation Corporate Bonds with a Total Face Value Not Exceeding RMB 6 Billion

Fosun Pharma announces that the China Securities Regulatory Commission has approved the company’s registration application for the public issuance of technology innovation corporate bonds with a total face value of no more than 6 billion RMB to professional investors. The approval is valid for 24 months from the date of registration approval, and the company may issue the bonds in installments within the registration validity period. The company will issue the bonds based on funding needs and market conditions and will fulfill disclosure obligations in a timely manner.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments